Clinical trials: Renal Transplant Rejection, open to volunteers
Antibody Mediated Rejection After Kidney Transplantation
Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, Study of Reactivity
Humoral rejection of kidney transplants is responsible for a large number of kidney graft losses in a context of increasing shortage.
- Trial name
- B-KiMi (NCT07134491)
- Testing
- Piece of kidney removal, Stool collection, Blood collection
- Where
- 2 sites in France
- Volunteers
- 45 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immunosuppression Management, Biomarkers / Blood
PIONEER Trial (Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients)
This is an observational, prospective, multi-center trial designed to evaluate clinical outcomes in kidney transplant recipients undergoing TruGraf and TRAC monitoring. Approximately 15 U.S. sites
- Conditions
- Immunosuppression Management, Biomarkers / Blood, Subclinical Rejection, Biopsy
- Trial name
- PIONEER (NCT07231328)
- Testing
- There is no required Intervention for this Protocol. Based on Results for TruGraf/TRAC/TRAC ID Investigators may use the results in managing subjects Immunosuppression or rule out rejection.
- Volunteers
- 600 people
- Sponsor
- Transplant Genomics, Inc.
Kidney Transplant Failure and Rejection
Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection
Background: Long-term success of organ transplantation is limited by the inexorable loss of graft function due to rejection. Prevalent dogma defends that allograft rejection is exclusively mediated by the adaptive immune system…
- Trial name
- STARR (NCT03955172)
- Testing
- Everolimus
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Acute Rejection of Renal Transplant, Graft Failure
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection
Acute rejection after kidney transplantation should ideally be diagnosed prior to immunologic injury in a non-invasive fashion in order to improve long-term graft function.
- Trial name
- NCT05084768
- Testing
- Donor-derived cell-free DNA
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Loma Linda University
End-stage Renal Disease (ESRD), Kidney Transplantation
Microbiota Changes Related to Outcomes in Kidney Transplantation
Chronic kidney disease affects approximately 10% of the world population. End-stage renal disease (ESRD) is associated with immune dysregulation, chronic inflammation, and alteration of the gut and urinary microbiota.
- Trial name
- MICRO-KT (NCT07893691)
- Testing
- Fecal samples, Urinary sample, Blood samples
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Urinary Tract Infections, Kidney Transplant Rejection
PRObiotics for KIdney Transplantation
The goal of this clinical trial is to assess if dietary supplememtation with OMNi-BiOTiC® 41167 reduces the risk of urinary tract infections in kidney transplant recipients.
- Conditions
- Urinary Tract Infections, Kidney Transplant Rejection, Kidney Transplant Infection, Dysbiosis
- Trial name
- ProKiT (NCT06825117)
- Testing
- OMNi-BiOTiC® 41167
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- University Hospital, Udine, Italy
Antibody-Mediated Rejection (AMR)
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Antibody-mediated rejection (AMR) is a major cause of worsening kidney function after a kidney transplant (kidney allograft dysfunction) and can lead to kidney failure.
- Trial name
- NCT07613359
- Testing
- Mezagitamab
- Where
- 35 sites in United States, China and 3 more
- Volunteers
- 36 people
- Sponsor
- Takeda
Kidney Transplant
Tissue Study on the Chronic Active Humoral Rejection (cAMR) Population of Kidney Transplantation
The study is tissue-based, retrospective and prospective, single-centre, non-sponsored. Primary objective: To examine patient and organ survival and eGFR variation in kidney transplant patients diagnosed histologically with cAMR.
- Trial name
- NCT06794970
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Kidney Transplant Rejection
Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized
The goal of this clinical trial is to determine whether belimumab can improve detection of circulating HLA-specific memory B cells to support safer and more effective donor organ allocation in highly sensitized kidney transplant…
- Trial name
- BE-MOBILYZED (NCT07539857)
- Testing
- Belimumab Prefilled Syringe [Benlysta]
- Where
- Netherlands
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Renal Transplant Rejection, Induction Therapy
Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies
Induction therapy decreases the rate of acute allograft rejection in kidney transplant recipients (KTRs) and is strongly recommended.
- Trial name
- INSTEAD (NCT05385432)
- Testing
- Rabbit Anti thymocyte globulin (rATG), Basiliximab
- Where
- France
- Volunteers
- 244 people
- Sponsor
- University Hospital, Tours
Antibody-mediated Rejection, Microvascular Inflammation
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and then developed antibody-mediated rejection (AMR) or microvascular inflammation (MVI).
- Trial name
- NCT07444489
- Testing
- Felzartamab
- Where
- 15 sites in United States, Canada
- Volunteers
- 201 people
- Sponsor
- Biogen
Renal-urinary Impairment, Graft Rejection
Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients
BK virus (BKV) is a ubiquitous virus that infects more than 80% of the population. In case of immunosuppression, BKV can replicate and induce nephropathies in renal transplant recipients or haemorrhagic cystitis in bone marrow…
- Conditions
- Renal-urinary Impairment, Graft Rejection, Infection Episodes
- Trial name
- BKV-Pneumo (NCT04164576)
- Testing
- Transplant patients
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Strasbourg, France
Short-term Graft Function, Metabolic Effects
Amino Acid Infusion in Kidney Transplant Recipients
The study addresses the impact of amino acid infusion in the early post-transplant period on graft function and the incidence of post-transplant complications.
- Conditions
- Short-term Graft Function, Metabolic Effects, Nutritional Effect, Immunological &Amp; Inflammatory Markers
- Trial name
- AID-KT (NCT06929637)
- Testing
- Infusion Therapy, Saline solution infusion
- Where
- Slovakia
- Volunteers
- 100 people
- Sponsor
- University Hospital, Martin
Chronic Antibody-mediated Rejection (cABMR)
Allogeneic Umbilical Cord Mesenchymal Stromal Cells for the Treatment of Chronic Antibody-Mediated Rejection in Kidney Transplantation
Kidney transplantation is the best treatment for end-stage chronic kidney disease (CKD), improving survival and quality of life, while reducing treatment costs.
- Trial name
- SCARR (NCT06886646)
- Testing
- Allogeneic Mesenchymal Stromal Cell Therapy
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Transplant Rejection
Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)
Antibody mediated rejection (ABMR) is a major cause of graft loss after kidney transplantation (KT) and is mainly associated with preformed anti-HLA donor specific antibodies (DSAs) (phenotype 1) or de novo DSAs (dnDSAs)…
- Trial name
- BELA-M-R (NCT06291103)
- Testing
- Conversion to Belatacep, Standard of care treatment (SOC regimen) with Tacrolimus
- Where
- France
- Volunteers
- 290 people
- Sponsor
- University Hospital, Rouen
BK Viremia, Kidney Transplant Infection
A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients
BEAT-BK will see the effect of immunosuppression reduction/modification with and without IVIG on BKPyV infection, allograft function, allograft loss, acute transplant rejection, immunosuppression load and death in kidney and…
- Conditions
- BK Viremia, Kidney Transplant Infection, Kidney Transplant Failure and Rejection
- Trial name
- BEAT-BK (NCT05325008)
- Testing
- Immunosuppression reduction/modification + intravenous immunoglobulin, Immunosuppression reduction/modification
- Where
- 13 sites in Australia
- Volunteers
- 280 people
- Sponsor
- The University of Queensland
Kidney Rejection Transplant
Molecular Landscape of Microvascular Inflammation in Kidney Allografts
Microvascular inflammation in kidney allografts has been widely reappraised in the recent update of Banff classification. There is a critical need to better understand the pathophysiological mechanisms associated with the various…
- Trial name
- NCT06342128
- Testing
- No intervention
- Where
- 3 sites in France
- Volunteers
- 600 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
End-Stage Renal Disease, End Stage Renal Disease on Dialysis
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk
This clinical trial investigates the transplantation of donor kidneys that have been genetically modified ex vivo using CRISPR-Cas9 genome editing to reduce immunogenicity and transplant rejection.
- Conditions
- End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney Transplant Rejection
- Trial name
- NCT07053462
- Testing
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney, Kidney Transplantation with Standard Care
- Where
- China
- Volunteers
- 90 people
- Sponsor
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Renal Transplant Rejection, Tolerance
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
The purpose of this study is to find out if an investigational treatment will allow kidney transplant recipients to better accept their new kidney and stop immunosuppressive medicines.
- Conditions
- Renal Transplant Rejection, Tolerance, Kidney Transplant
- Trial name
- NCT03707262
- Testing
- Donor CD34+ and CD3+ cells
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jeffrey Veale, MD
Posttransplant Diabetes Mellitus, Acute Graft Rejection
Silymarin's Advantage on Graft Effectiveness
The study examines the impact of silymarin supplementation during the early post-transplant period, administering 900 g daily for 30 days under standard treatment.
- Conditions
- Posttransplant Diabetes Mellitus, Acute Graft Rejection, Biopsy Proven Acute Rejection, Antibody Mediated Rejection of Kidney Transplant
- Trial name
- SAGE (NCT06801886)
- Testing
- Silymarine supplementation
- Where
- Slovakia
- Volunteers
- 130 people
- Sponsor
- University Hospital, Martin